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Background: The relative risk of acute kidney injury (AKI) following different infections, 
and whether angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers 
(ARBs) modify the risk, is unclear. We aimed to determine the risks of hospital admission with 
AKI following infections (urinary tract infection [UTI], lower respiratory tract infection [LRTI], 
and gastroenteritis) among users of antihypertensive drugs.
Methods: We used UK electronic health records from practices contributing to the Clinical 
Practice Research Datalink linked to the Hospital Episode Statistics database. We identified 
adults initiating ACEIs/ARBs or alternative antihypertensive therapy (β-blockers, calcium 
channel blockers, or thiazide diuretics) between April 1997 and March 2014 with at least 
1 year of primary care registration prior to first prescription, who had a hospital admission for 
AKI, and who had a primary care record for incident UTI, LRTI, or gastroenteritis. We used 
a self-controlled case series design to calculate age-adjusted incidence rate ratios (IRRs) for 
AKI during risk periods following acute infection relative to noninfected periods (baseline). 
Results: We identified 10,219 eligible new users of ACEIs/ARBs or other antihypertensives 
with an AKI record. Among these, 2,012 had at least one record for a UTI during follow-up, 
2,831 had a record for LRTI, and 651 had a record for gastroenteritis. AKI risk was higher 
following infection than in baseline noninfectious periods. The rate ratio was highest fol-
lowing gastroenteritis: for the period 1–7 days postinfection, the IRR for AKI following 
gastroenteritis was 43.4 (95% CI=34.0–55.5), compared with 6.0 following LRTI (95% 
CI=5.0–7.3), and 9.3 f ollowing UTI (95% CI=7.8–11.2). Increased risks were similar for dif-
ferent antihypertensives.
Conclusion: Acute infections are associated with substantially increased transient AKI risk 
among antihypertensive users, with the highest risk after gastroenteritis. The increase in relative 
risk is not greater among users of ACEIs/ARBs compared with users of other antihypertensives.
Keywords: acute kidney injury, angiotensin-converting enzyme inhibitors, angiotensin receptor 
antagonists, infection, self-controlled case series
Plain language summary
A sudden decrease in kidney function, known as “acute kidney injury” (AKI), is common and 
associated with an increased risk of death, prolonged hospital stay, and risk of permanent kid-
ney failure. One of the common causes of AKI is thought to be severe infections, particularly 
gastroenteritis. However, the degree of increased risk after infections is not known. In addition, 
some evidence suggests that AKI can occur as a side effect of angiotensin-converting enzyme 
inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), medications commonly used for 
treating conditions such as high blood pressure and heart problems. It is thought that AKI risk is 
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particularly increased among people taking these drugs who develop 
severe infections. Therefore, we examined the relative risk of AKI 
after urinary tract and chest infections, and gastroenteritis. We also 
compared the relative risk of AKI after these infections for patients 
taking a range of blood pressure drugs. Our results show that there 
is a substantially increased risk of AKI immediately after all three 
infections, which is particularly marked after gastroenteritis. How-
ever, the level of increased risk of AKI after infection was similar in 
users of ACEIs/ARBs and other blood pressure drugs. Our results 
suggest that clinicians need to be aware of AKI risk after common 
infections and that this risk applies to patients taking all classes of 
antihypertensives. 
Introduction
Acute kidney injury (AKI) is a rapid (within hours or days) 
deterioration in kidney function, associated with increased 
mortality,1,2 prolonged hospital stay,3,4 and the risk of chronic 
kidney disease.5 AKI has been observed in up to 20% of UK 
adult hospital admissions.1,6,7 Sepsis and diarrhea leading to 
hypovolemia are risk factors for AKI, and this is considered 
to be particularly important for patients taking drugs such 
as angiotensin-converting enzyme inhibitors (ACEIs) and 
angiotensin receptor blockers (ARBs).8 There is an increased 
focus on early detection and better management of AKI in 
primary care.9–12 However, AKI risk among patients present-
ing to general practitioners (GPs) with common infections 
is unknown. In addition, the extent to which this risk is 
increased among patients prescribed ACEIs/ARBs compared 
with users of other antihypertensive drugs is unclear. This 
information is needed to allow health care professionals to 
identify patients at a high risk of AKI. 
We used a self-controlled case series (SCCS) design13 to 
assess the risk of AKI associated with three different types of 
acute infection: urinary tract infection (UTI), lower respira-
tory tract infection (LRTI), and gastroenteritis. Using this 
method, we compared the incidence of AKI during periods 
of infection compared with that during noninfected (baseline) 
periods within individual patients. This limits the potential 
confounding effect of characteristics that vary between 
individuals, such as comorbidities and risk factors for renal 
disease.14 We also investigated how the relative risk of AKI 
associated with acute infection differed in ACEI/ARB users 
compared with the risk in users of other antihypertensives, 
which are prescribed for similar indications and not con-
sidered substantial risk factors for AKI.8 In addition, we 
investigated whether diabetes, cardiac failure, chronic kidney 
disease, and concurrent prescription of loop diuretics modi-
fied the infection-specific increase in the relative risk of AKI.
Methods
Study design and setting
We undertook an SCCS study using computerized clini-
cal records from adults attending primary care practices 
contributing to the UK Clinical Practice Research Datalink 
(CPRD) and linked hospital record data from the Hospital 
Episode Statistics (HES) database. CPRD is a database of 
primary care electronic health record data from 7% of the 
UK population.15 Included patients are largely representative 
of the UK population.15–17 HES records cover all admissions 
for National Health Service (NHS)-funded patients treated 
either in English NHS trusts or by independent providers.18 
Seventy-five percent of English general practices included 
in CPRD are linked to HES data.15 The study period was 
from April 1, 1997, to March 31, 2014. CPRD data are ano-
nymized before being supplied to researchers. Researchers 
do not have access to names, addresses, or dates of birth 
(although the year of birth is available). Primary care data 
are linked with hospital record data by a trusted third party 
in an approved manner.
Participants, exposures, and outcomes
We identified all adults (aged ≥18 years) with a first prescrip-
tion for an ACEI/ARB or other antihypertensive (β-blocker, 
calcium channel blocker [CCB], or thiazide diuretic) between 
April 1997 and March 2014, who had a hospital admission 
for AKI and a primary care record for incident UTI, LRTI, 
or gastroenteritis.
To ensure that we had reliable measures of drug use and 
incident morbidity, we required that all participants had at 
least 1-year continuous registration in CPRD before the first-
recorded antihypertensive prescription (ACEI/ARB, β-blocker, 
CCB, or thiazide diuretic) and that they be registered with a 
practice meeting CPRD’s quality control standards. Follow-up 
started at first prescription for an antihypertensive drug and 
ended at the earliest of the following: 1) first break in antihy-
pertensive therapy of >60 days; 2) death; 3) left practice; 4) 
last data collection from practice; or 5) diagnosis of end-stage 
renal disease (ESRD; Supplementary materials). We excluded 
patients with ESRD prior to study entry. 
ACEI/ARB or other antihypertensive users
We calculated prescription duration using the quantity of 
medication prescribed and daily dose recorded; when these 
data were not available, we assumed the population median 
prescription duration (28 days). Exposure to medications 
was assumed to start on the date of the prescription. We 
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constructed continuous courses of therapy by allowing for 
a 60-day gap between consecutive prescriptions (≤60 days 
between the end of one prescription and start of the next) to 
allow for stockpiling of drugs and nonadherence.
We classified individuals as ACEI/ARB users from their 
first ACEI/ARB prescription until their first break in continu-
ous therapy of >60 days, regardless of concomitant β-blocker, 
CCB, or thiazide diuretic prescriptions. Individuals were 
identified as users of other antihypertensives (β-blockers, 
CCBs, or thiazide diuretics) from their first non-ACEI/ARB 
antihypertensive prescription until either their first ACEI/
ARB prescription (at which point they were classified as 
ACEI/ARB users) or their first break in continuous antihyper-
tensive therapy of >60 days. If a non-ACEI/ARB user did not 
have an AKI event during their first course of antihypertensive 
therapy with a specific drug class, they were considered for 
inclusion in the study in subsequent first courses of therapy 
with alternative drug classes (eg, if an individual had a new 
course of β-blocker therapy during which no AKI event 
occurred, they could be included if they had an AKI event 
during a subsequent new course of CCB therapy).
Exposure
We identified acute infections using morbidity coding in 
primary care (Read codes). We assumed records separated 
by ≤28 days represented the same episode of infection; the 
incident date of infection was taken to be the first in a series 
of consecutive records separated by ≤28 days. 
Gastroenteritis was identified using an algorithm that 
employed the following types of code: 1) definite – codes 
that definitely represent gastrointestinal infection (eg, J43 
– gastroenteritis); 2) symptom – codes that represent symp-
toms of gastroenteritis (eg, 19F – diarrhea); and 3) Pathogen 
– codes that represent specific microbiological causes of 
gastroenteritis (eg, A070 – Escherichia coli gastrointestinal 
tract infection). Gastroenteritis was defined using either of the 
following: 1) a single definite gastroenteritis code within the 
infection episode, recorded as part of a general practice con-
sultation only (we excluded any records that might not rep-
resent a contemporaneous record of the patient’s condition; 
eg, we excluded records of hospital letters as their content 
may represent a past condition). If there was a symptom code 
recorded in the preceding 28 days (ie, earlier in the infection 
episode), the infection was assumed to have started on the 
earliest date the symptom was recorded within the infection 
episode; or 2) a combination of a symptom code followed by 
a record of a pathogen code in the subsequent 28 days. The 
symptom code must have been recorded as part of a general 
practice consultation (ie, not part of a letter). 
Due to the absence of pathogen codes for UTI or LRTI, 
these infection episodes were therefore defined using diag-
nostic Read codes for these infections, with the first of these 
codes (again recorded as a general practice consultation, ie, 
excluding hospital letters) indicating an incident infection. 
Outcome
We defined AKI as the first AKI International Classification 
of Diseases Version 10 (ICD-10) morbidity code recorded in 
an inpatient episode that started within 7 days of the start of 
a hospital admission (HES data) using N17 and N19 codes 
recorded in any diagnostic position. The SCCS method 
requires that multiple outcomes be independent of one 
another;14 because having one AKI event may alter the prob-
ability of having a subsequent AKI event, this assumption 
does not hold; therefore, we applied the established method 
of analyzing only the first AKI event for each patient.14
Comorbidities and demographics
For descriptive purposes, we identified sex, preexisting 
diabetes mellitus, ischemic heart disease, cardiac failure, 
hypertension, arrhythmia, decreased renal function (estimated 
glomerular filtration rate [eGFR] <60 mL/min/1.73 m2), the 
number of episodes of each type of infection during follow-up, 
and the number of AKI hospital admissions during follow-up. 
Diabetes mellitus, ischemic heart disease, cardiac failure, 
hypertension, and arrhythmia were identified using primary 
care and in-hospital morbidity coding prior to study entry. 
Renal function was established by calculating eGFR using the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation.19 We used serum creatinine results recorded in 
the 12 months before first ACEI/ARB or other antihyperten-
sive prescription to calculate eGFR (using either the highest 
eGFR from the most recent two serum creatinine results or, 
if only one creatinine result was available, the single most 
recent serum creatinine recorded prior to first prescription).
Current age was derived from date of birth and was 
included in all analyses as a time-varying covariate in the 
following age bands: 18–44, 45–54, 55–59, 60–64, 65–69, 
70–74, 75–84, 85–89, and 90+ years. Time-varying diabetes 
mellitus, cardiac failure and loop diuretic exposure, and 
baseline renal function were included in secondary analyses. 
Diabetes and cardiac failure were defined as time-updated 
variables representing “ever diagnosed,” with status chang-
ing with the first-recorded code for each condition. Loop 
diuretic exposure was identified using continuous courses 
of loop therapy defined allowing for a 60-day gap between 
 consecutive prescriptions. Baseline renal function was clas-
sified as eGFR above or below 60 mL/min/1.73 m.2
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We have made code lists for all variables available for 
download (https://doi.org/10.17037/DATA.211). 
Statistical analysis
SCCS methodology is based on that used in cohort stud-
ies. It relies on making comparisons within individuals in a 
population of people who experience both the outcome and 
the exposure. Incidence rate ratios (IRRs) are calculated 
using conditional Poisson regression to compare the rate 
of events during exposed periods to rates observed during 
unexposed periods.14 This removes all fixed between-person 
confounding, ie, differences between people who did and did 
not have infections (such as comorbidities and risk factors 
for renal disease). 
We defined a 1-month exposed period starting the day 
after infection diagnosis and subdivided it into three risk 
windows: 1–7, 8–14, and 15–28 days postinfection. All other 
observation times made up the baseline (unexposed) period, 
with the exception of the day of and the 7 days before infec-
tion diagnosis. We separated the 7 days prior to infection 
diagnosis from baseline time because infections may begin 
earlier than the date when an individual presents to their GP; 
therefore, during this time, they may be at a different risk 
of AKI, leading to possible bias in the baseline rate of AKI. 
Events recorded on the same day may have occurred on dif-
ferent days sometime prior to the GP visit but are recorded 
on the day of the consultation; we therefore also separated 
out the day of infection diagnosis from other follow-up 
time. Figure 1 illustrates the observation period for a single 
individual.
For each infection, we calculated the IRR comparing 
the rate of AKI in each risk window to baseline time using 
conditional Poisson regression and adjusting for age.
Sensitivity analyses
We tested the impact of our AKI definition by repeating 
the main analysis: 1) limiting the defining ICD-10 codes to 
N17 codes only, which have been shown to have a high posi-
tive predictive value for AKI;20 and 2) restricting to codes 
recorded in the top two diagnostic positions of any hospital 
episode starting within 7 days of admission. We also varied 
the period over which we assumed continued antihyperten-
sive exposure, allowing periods of 30 or 90 days between 
consecutive prescriptions. In addition, we repeated the main 
analysis including calendar period as a covariate to adjust for 
the many changes in clinical, diagnostic, and administrative 
practices over the study period that may influence number of 
reported AKI cases and the recording of incident infections 
(using the following time periods: 1997–2000, 2001–2004, 
2005–2008, 2009–2011, and 2012–2014). Finally, the SCCS 
Figure 1 Graphical representation of self-controlled case series study design.
Notes: Figure illustrates a single individual with an acute infection (UTI, LRTI, or gastroenteritis) during their observation period. All participants included in the analyses 
had at least one acute infection and at least one episode of AKI requiring hospital admission (analyses used first episode of AKI as the outcome and ignored subsequent 
AKI records). Rate ratios presented are pooled estimates derived from the rate of AKI events during risk (exposed) periods divided by the rate of events during baseline 
periods; age is adjusted for at all stages of analysis. Incident AKI can occur during any one of six exposure periods: baseline, 7 days prior to infection, day of infection, 1–7 
days postinfection, 8–14 days postinfection, or 15–28 days postinfection. *Follow-up ends at the earliest of death, the end of registration, last collection date from GP, or 
30/60/90 days after the end of first break in ACEI/ARB or CCB treatment of 30/60/90 days or more.
Abbreviations: ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; AKI, acute kidney injury; CCB, calcium channel blocker; GP, general 
practitioner; LRTI, lower respiratory tract infection; UTI, urinary tract infection.
1
Start of observation:
New ACEI/ARB
or CCB
prescription
Acute infection
diagnosis
Acute infection
diagnosis
End of observation*
Time
Baseline period
Pre-exposure period of 7 days. Preinfection plus day of acute infection diagnosis 
Exposed period divided into three risk windows following acute infection: 1=1–7 days postinfection;
2=8–14 days; and 3=15–28 days
2 3
1 2 3
1 2 3
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method requires that each individual’s observation period is 
independent of the outcome, an assumption that could be 
violated by fatal AKI events. Therefore, we excluded those 
who died within 90 days of their AKI event to assess the 
effect of censoring due to death.
Secondary analyses
We undertook stratified analyses to explore whether the risk 
of AKI during periods of acute infection differed in the fol-
lowing groups: 1) ACEI/ARB users compared with other anti-
hypertensive users; 2) those with and without cardiac failure 
and diabetes mellitus; 3) those with low baseline eGFR (<60 
mL/min/1.73 m2); and 4) the use of a loop diuretic. In each 
instance, we calculated IRRs (adjusted for age) stratified by 
each binary variable using a model including an interaction 
between risk period and the stratifying variable and p-values 
(from likelihood ratio tests) to investigate whether the inter-
action explained more of the variability in AKI during risk 
periods compared with baseline time. 
Post hoc we were concerned that our comparison group of 
users of non-ACEI/ARB antihypertensive drugs (β-blockers/
CCBs/thiazides) was heterogeneous and likely to include 
many frail patients at a high risk of infection and AKI. There-
fore, we repeated the analysis comparing ACEI/ARB users 
to users of CCBs only. Initially, CCB users were defined in 
the same way as that used in the main study population (refer 
to the section “ACEI/ARB or other-antihypertensive users”). 
We then repeated the analysis again, but this time included 
only follow-up time from the first study drug prescribed 
(ACEI/ARB or CCB) and censored at any change in study 
drug prescribing (eg, change from one class of study drug 
to the other or addition of other study drug).
Data management and analyses were performed using 
Stata Version 14 (StataCorp LP, College Station, TX, USA).
Ethical approval
This study was approved by the London School of Hygiene 
and Tropical Medicine Research Ethics Committee (Refer-
ence 6536) and by the CPRD Independent Scientific Advisory 
Committee (ISAC; Protocol Number: 15_146).
Results
From a cohort of 623,951 eligible new users of antihyperten-
sives, we identified 10,219 individuals with a record of AKI 
in the CPRD database (Figure 2). Among these, 2,012 had 
at least one record for a UTI during follow-up, 2,831 had a 
record for an LRTI, and 651 had a record for gastroenteritis. 
The population was elderly with a mean baseline age of 70–75 
years and a high prevalence of comorbidities (Table 1). ACEI/
ARB users were more likely than users of other antihyper-
tensives to have comorbidities (diabetes mellitus, ischemic 
heart disease, arrhythmia, hypertension, and cardiac failure) 
at first antihypertensive prescription.
AKI risk was higher following infection than in baseline 
noninfectious periods (Figure 3). AKI rate ratio was highest 
following gastroenteritis; for the period 1–7 days postinfec-
tion, IRR for gastroenteritis was 43.3 (95% CI=34.0–55.5), 
compared with 6.0 in LRTI (95% CI=5.0–7.3) and 9.3 in UTI 
(95% CI=7.8–11.2). In the 7 days prior to infection, relative 
AKI risk was between 3 and 4 times higher (depending 
on infection type) than during baseline time, and AKI risk 
decreased over time following infection.
Changing the definition of AKI, allowing periods of 30 
or 90 days (instead of 60) between consecutive prescriptions 
to define eligible follow-up time, additionally including 
calendar period as a covariate or excluding those who died 
within 90 days of their AKI event made minimal difference 
to the results (Table S1).
For LRTI and gastroenteritis, stratifying on the class of 
antihypertensive prescribed at baseline revealed no evidence 
of a difference in AKI risk in ACEI/ARB users compared 
with users of other antihypertensives (p-values for interac-
tion: LRTI, p=0.784; gastroenteritis, p=0.879). For example, 
in the in the 1–7 days following LRTI, the IRR for AKI in 
non-ACEI/ARB users was 6.3 (95% CI=4.3–9.3) compared 
with 6.0 (95% CI=4.8–7.3) in ACEI/ARB users, while 
 following gastroenteritis the IRR for AKI in non-ACEI/
ARB users was 35.4 (95% CI=19.2–65.3) compared with 
45.2 (95% CI=34.6–59.1) in ACEI/ARB users (Table S2; 
Figure S1). There was little difference in effect estimates 
if we varied the definition used to identify non-ACEI/ARB 
users (Table S3).
There was some limited evidence of a difference in 
AKI risk in ACEI/ARB users compared with users of other 
antihypertensives following UTI (p-value for interaction: 
p=0.021). In the 1–7 days following UTI, the IRR for AKI in 
non-ACEI/ARB users was 7.4 (95% CI=5.1–10.7), compared 
with 10.0 (95% CI=8.2–12.4) in ACEI/ARB users (Table S2). 
However, there was no evidence for a difference in AKI risk 
between ACEI/ARB and non-ACEI/ARB users following 
UTI after varying the definition used to identify non-ACEI/
ARB users (p-values for interaction: p=0.276 after defining 
non-ACEI/ARB users as CCB users; p=0.558 after defin-
ing non-ACEI/ARB users as CCB users and only including 
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follow-up for the first drug prescribed [either ACEI/ARB or 
CCB]; Table S3).
After stratifying on cardiac failure, diabetes, loop 
diuretic exposure, and impaired baseline renal function 
(eGFR<60 mL/min/1.73 m2), there was some evidence of 
a difference in AKI risk in the sicker compared with the 
healthier subgroups in the first week of infection (Table S2); 
with some exceptions, the relative risk of AKI was lower in 
sicker subgroups. For example, 1) compared with nondiabet-
ics, AKI risk was lower in diabetics in the week following 
LRTI or gastroenteritis, but higher in diabetics following 
UTI; 2) AKI risk was lower in those with cardiac failure than 
those without following any UTI, LRTI, or gastroenteritis; 3) 
following LRTI or gastroenteritis, the risk of AKI was lower 
in those on loop diuretics compared with nonloop users; and 
4) following gastroenteritis, the risk of AKI was lower in 
those with worse renal function.
Discussion
Our results show a substantially increased risk of hospital 
admission with AKI following periods of acute infection 
in the community. While this is widely believed to be the 
case, to our knowledge, this is the first study to quantify 
this risk. The risk of AKI was 43 times higher in the week 
following gastroenteritis compared with baseline time, but 
in addition, it was also substantially increased after UTI and 
LRTI. The magnitude of the increased risk of AKI following 
acute infection was similar for users of ACEI/ARBs or other 
antihypertensives.
Strengths and weaknesses
A major strength of our study is the use of the SCCS design. 
Because this design compares risk within individuals at 
different times, results are less influenced by confounding 
from differences between comparison groups than traditional 
Figure 2 Identification of study participants.
Note: UTI, LRTI, and gastroenteritis are analyzed as separate outcomes.
Abbreviations: ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; AKI, acute kidney injury; BB, β-blocker; CCB, calcium channel blocker; 
CPRD, Clinical Research Practice Datalink; ESRD, end-stage renal disease; HES, Hospital Episode Statistics; LRTI, lower respiratory tract infection; UTI, urinary tract infection.
1,373,441
Individuals in CPRD aged ≥18 years with first
prescription for ACEI/ARB, BB, CCB or thiazide
between April 1, 1997, and  March 31, 2014 
523,011
Not eligible for HES linkage
223,192
Eligible follow-up time outside study
period or index date outside eligible
follow-up time
3,287
ESRD diagnosis prior to index date
613,732
No AKI episode recorded within follow-up
850,430
Individuals remaining
(representing: 466,271 ACEI/ARB users; 359,025 BB users;
225,656 CCB users; and 214,592 thiazide users)
627,238
Individuals remaining
623,951
Individuals remaining
10,219
Individuals with AKI during follow-up
2,012
At least one UTI
record in follow-up
2,831
At least one LRTI
record in follow-up
651
At least one
gastroenteritis
record in follow-up
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cohort designs. Therefore, differences in the prevalence of 
shared causes of infection and AKI risk, such as diabetes or 
other comorbidities, between the antihypertensive classes 
should not explain our results. Further, our study used routine, 
prospectively collected clinical data from a large UK general 
practice database that is broadly representative of the UK 
population.15 Our results, therefore, reflect real-world clini-
cal practice and are likely to be generalizable. The baseline 
characteristics of the study population demonstrate that they 
are elderly with a high prevalence of comorbidities and so are 
representative of those known to be at a high overall risk of 
AKI. However, we studied only people taking antihyperten-
sives, and it is possible that the risk of AKI after infections 
is different in healthier people not taking these medications.
We examined only three of the commonest infections 
(UTI, LRTI, and gastroenteritis)21–24 and so cannot comment 
on the risks of AKI following other infections. We used ICD-
10 coding alone to define AKI; therefore, we have captured 
Figure 3 Main analysis: age-adjusted incidence rate ratios (95% CI) for AKI in risk periods after acute community-acquired infections (gastroenteritis, urinary tract infection, 
and lower respiratory tract infection).
Notes: The numbers of participants exposed to each type of infection are shown in parentheses for each exposure. These include a small number who had a recorded AKI 
event on the day of infection exposure that was not included in the analysis, because the events may have been recorded retrospectively. Incidence during the baseline period 
served as the reference category. IRR denotes age-adjusted incidence ratio; age-adjusted in the following age bands: 18–44, 45–54, 55–59, 60–64, 65–69, 70–74, 75–84, 85–89, 
and 90+ years. Participants may appear within more than one category.
Abbreviations: AKI, acute kidney injury; IRR, incidence rate ratio.
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only a small proportion of the cases defined by current 
biochemical definitions of AKI. However, the vast majority 
of cases were identified using a code that has high positive 
predictive value for AKI and includes a greater proportion 
of more severe cases.25,26 While AKI coding patterns have 
changed markedly over recent years,27 adjusting for calendar 
period, or restricting to the top two diagnostic code posi-
tions, did not affect our results. We examined only the risk 
associated with patients’ first episode of AKI; therefore, these 
results may not be representative of risks for patients with 
recurrent AKI admissions. 
It is possible that patients who subsequently developed 
AKI had features of sepsis when they visited their GP with 
infection. However, clinically evident sepsis is unlikely to 
explain our results since immediate hospital admission was 
not arranged (we separated out individuals with hospital AKI 
recorded on the same day as their primary care infection 
record). Our assessment of drug exposure was based on pre-
scriptions alone. We cannot be certain that those prescribed a 
drug were taking the medication; crucially we were unable to 
capture any temporary discontinuation in medication use dur-
ing acute illness. However, advice to withhold ACEIs/ARBs 
during acute illness (sick-day rules) is recent, and we did not 
see any change in our results after adjusting for calendar 
period. We made assumptions about likely exposure status 
for all drugs during apparent gaps in prescribing records. We 
chose to consider gaps of ≤60 days as indicating continued 
treatment, but alternative assumptions about the continuous 
treatment period had no substantial effect on our results.
Finally, there may be systematic differences between 
ACEI/ARB users and patients taking other antihypertensives. 
To make our results generalizable, patients taking ACEI/
ARB were classified into this group regardless of other 
antihypertensive use. This group had a higher prevalence of 
comorbidities and were likely to have been taking more drugs 
overall than users of other antihypertensives. In addition, to 
minimize differences between groups, we allowed users of 
other antihypertensives to subsequently become ACEI/ARB 
users, but (as ACEI/ARB cessation may be associated with 
increased frailty and AKI risk28) we did not allow those who 
stopped the drugs to be classed as users of other antihyperten-
sives. ACEI/ARB users were therefore followed up for longer, 
with more time to develop further comorbidities (which are 
themselves risk factors for AKI) or to become increasingly 
frail. A sensitivity analysis to examine the impact of this, 
restricting to follow-up time from first study drug prescribed 
(ACEI/ARB or CCB) to any change in study drug prescrib-
ing, showed little difference in effect estimates. Nonetheless, 
these differences between the groups mean that it is likely that 
those using ACEI/ARB had a higher absolute rate of AKI in 
all time periods. This could have resulted in a lower IRR for 
AKI following infections in ACEI/ARB users compared with 
the risk ratio for users of other antihypertensives.
Results in context
Among critically ill patients, there is a clearly established 
causal link between sepsis and AKI29–35 with approximately 
half of AKI cases related to sepsis.29,30,32,35 AKI has also been 
shown to be common in those with less severe infections.36,37 
There is evidence that in intensive care patients with AKI the 
most common source of sepsis is the lung.31,32,34
Our study design can only investigate the relative effect 
on AKI risk of each infection. However, the absolute rates 
of AKI and therefore public health impact depend on the 
incidence of each infection. LRTIs are the leading infection-
related cause of disability-adjusted life years in England38 and 
lead to more hospitalizations than UTIs or gastroenteritis;39 
therefore, while the relative risk of AKI following gastroen-
teritis may be higher than that following LRTI, LRTI may 
be associated with more AKI events than gastroenteritis or 
UTI. Similarly, UTIs are common in young women and those 
with diabetes,40 therefore, UTIs may be related to more AKI 
events in these groups than LRTIs or gastroenteritis.
Explanations and implications
We found that, compared with baseline noninfected time, 
patients with gastroenteritis had a much higher risk of AKI 
following infection than those with UTI or LRTI. This is 
likely to relate to the differences in physiological disturbance 
caused by the different infections, with substantial volume 
depletion following gastroenteritis. In addition, there may 
be differences in primary care consulting behavior, or sub-
sequent detection bias, meaning that patients with diarrhea 
are more likely to have diagnosed or recorded AKI compared 
with patients with UTI or LRTI.
These data also demonstrate some counterintuitive 
results. Compared with baseline noninfected time, we found 
that the relative risk of AKI was higher in the 7 days prior to 
infection diagnosis. This may have occurred if a proportion 
of patients were admitted directly to hospital with AKI and 
then consulted their GP in the week following their hospital 
admission for related or new infection symptoms. This would 
have led to capture of a hospital AKI record followed by a 
primary care infection code. If the initial hospital admission 
was related to infection, we would underestimate the associa-
tion of infection with AKI in our results.
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Our results also showed that the relative risk of AKI in 
the first week following infection compared with baseline 
noninfected time was, in general, slightly lower in predefined 
groups at a higher risk of AKI: cardiac failure, diabetes, 
additional loop diuretic exposure, and impaired baseline renal 
function.28 As discussed above, a lower degree of increased 
AKI risk after infection might be explained by patients with 
these chronic health conditions being more likely to have 
admissions for AKI during baseline time. Alternately, sicker 
patients might have been more likely to be sent to hospital by 
their GP on the day of their infection diagnosis or to bypass 
their GP by going straight to hospital. Since we separated 
out the day of infection diagnosis from other follow-up time 
and individuals without a primary care infection diagnosis 
were excluded from the study, we potentially systematically 
excluded sicker individuals both from postinfection risk 
periods and from inclusion in our study. Both explanations 
would again suggest that our estimates of the increase in the 
risk of AKI following infection are likely to be conservative. 
However, while we found that the relative impact of infection 
on AKI risk was, in general, slightly lower in sicker groups, 
those in subgroups with these comorbidities will be at higher 
absolute baseline risk of AKI; therefore, any relative increase 
will have proportionally more impact.
While our results showed no evidence of effect modi-
fication by ACEI/ARB use in the risk of AKI following 
LRTI (the analysis with the greatest number of events) or 
gastroenteritis, we did find statistical evidence of effect 
modification by ACEI/ARB use for AKI following UTI. 
However, differences in the effect estimates between ACEI/
ARB users and those of other antihypertensives at each time 
point were small. After limiting the comparison group with 
those on CCBs only there was no longer any evidence for a 
difference in AKI risk between ACEI/ARB and non-ACEI/
ARB users following UTI. In addition, given the multiple 
comparisons undertaken, we do not believe that our results 
demonstrate any evidence that people on ACEI/ARBs have 
a greater increase in the risk of AKI following infection 
than those on other antihypertensives. However, it is pos-
sible that due to differences between people taking different 
antihypertensives we have failed to detect a true difference. 
Nonetheless, if ACEI/ARB use was a strong risk factor for 
AKI after infection, we might have expected to see evidence 
of an interaction between antihypertensive group and the 
level of increased risk of AKI, as we have done for other 
known risk factors.
Current guidelines for health care professionals recom-
mend that patients with hypovolemia, sepsis, and possible 
urological obstruction and those taking potentially nephro-
toxic drugs should be considered to be a particular risk of 
AKI.8 Similarly, self-management guidelines for patients 
taking ACEI/ARBs, nonsteroidal anti-inflammatory drugs, 
diuretics, or metformin advise patients to stop taking these 
medications if they develop vomiting, diarrhea, or “fever, 
sweats, and shaking.”41 Our results confirm the need to 
emphasize gastroenteritis as a potent risk factor for AKI. 
However, they also suggest that current guidance should be 
broadened to include other types of infection. In addition, our 
results support previous research that patient characteristics 
are a much more important risk factor for AKI than specific 
classes of antihypertensive drugs. 
Conclusion
In conclusion, among antihypertensive users in primary 
care, UTI, LRTI, and gastroenteritis are all associated with 
a substantially increased risk of hospital admission with 
AKI. The level of increased risk is similar for both ACEI/
ARB users and users of other antihypertensives. Clinicians 
should be aware of the increased risk of AKI in anyone with 
symptoms of these infections. 
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Figure S1 Age-adjusted incidence rate ratios (95% CI) for AKI in risk periods after community-acquired infections stratified by ACEI/ARB or other antihypertensive use.
Note: Other antihypertensives: β-blockers, calcium channel blockers, or thiazide diuretics.
Abbreviations: ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; AKI, acute kidney injury.
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Acute kidney injury following infections
Table S1 Age-adjusted incidence rate ratios (95% CIs) for AKI during risk periods compared with baseline time in the main analysis 
and additional sensitivity analyses
Risk period Urinary tract 
infection
Lower respiratory 
tract infection
Gastroenteritis
Main analysis: AKI defined using N17 and N19 codes 
in any diagnostic position in any episode starting 
within 7 days of hospital admission; 60-day follow-up 
definitiona
n=2,012 n=2,831 n=651
Baseline period Reference Reference Reference
Days after infection:
1–7 9.31 (7.76, 11.17) 6.03 (5.01, 7.25) 43.43 (34.00, 55.48)
8–14 4.09 (3.19, 5.23) 3.07 (2.42, 3.89) 7.37 (4.50, 12.05)
15–28 2.72 (2.18, 3.40) 1.90 (1.52, 2.36) 4.50 (2.85, 7.10)
ICD-10 N17 AKI: AKI defined using N17 codes only 
in any diagnostic position in any episode starting 
within 7 days of hospital admission; 60-day follow-up 
definitiona
n=1,583 n=2,154 n=531
Baseline period Reference Reference Reference
Days after infection:
1–7 10.72 (8.79, 13.09) 6.84 (5.56, 8.41) 47.58 (36.32, 62.34)
8–14 4.85 (3.72, 6.33) 3.32 (2.53, 4.36) 8.65 (5.11, 14.64)
15–28 3.07 (2.40, 3.92) 2.05 (1.60, 2.64) 4.79 (2.87, 7.97)
Top diagnostic position: AKI defined using N17 
and N19 codes recorded in the top two diagnostic 
positions in any episode starting within 7 days of 
hospital admission; 60-day follow-up definitiona
n=891 n=1,086 n=288
Baseline period Reference Reference Reference
Days after infection:
1–7 10.42 (8.02, 13.53) 5.98 (4.42, 8.08) 62.81 (44.01, 89.65)
8–14 4.18 (2.89, 6.04) 3.18 (2.18, 4.65) 11.14 (5.62, 22.07)
15–28 2.95 (2.14, 4.07) 2.15 (1.53, 3.01) 7.75 (4.25, 14.13)
30-day follow-up: follow-up ends at the earliest of 
death, the end of registration, last collection date 
from GP, or 30 days after end of first break in the 
treatment of ≥30 days (main analysis uses 60 days)
n=1,095 n=1,466 n=318
Baseline period Reference Reference Reference
Days after infection:
1–7 8.26 (6.53, 10.45) 7.28 (5.82, 9.12) 53.12 (38.31, 73.65)
8–14 3.59 (2.61, 4.94) 3.05 (2.23, 4.18) 12.49 (7.26, 21.48)
15–28 2.43 (1.82, 3.22) 2.17 (1.65, 2.86) 6.03 (3.45, 10.53)
90-day follow-up: follow-up ends at the earliest of 
death, the end of registration, last collection date 
from GP, or 90 days after end of first break in the 
treatment of ≥90 days (main analysis uses 60 days)
n=2,444 n=3,468 n=805
Baseline period Reference Reference Reference
Days after infection:
1–7 9.04 (7.62, 10.72) 5.78 (4.85, 6.87) 43.08 (34.36, 54.00)
8–14 4.09 (3.26, 5.14) 2.95 (2.36, 3.68) 8.70 (5.69, 13.29)
15–28 2.66 (2.16, 3.26) 1.86 (1.52, 2.28) 4.48 (2.93, 6.84)
Calendar period: Adjusted for calendar period in 
addition to age;b main AKI definition; 60-day follow-
up definitiona
n=2,012 n=2,831 n=651
Baseline period Reference Reference Reference
Days after infection:
1–7 8.46 (7.05, 10.15) 5.59 (4.64, 6.73) 41.72 (32.52, 53.52)
8–14 3.71 (2.90, 4.75) 2.83 (2.23, 3.59) 7.06 (4.30, 11.58)
15–28 2.47 (1.98, 3.08) 1.73 (1.38, 2.15) 4.27 (2.70, 6.76)
Excluding early deaths: excludes all those who died 
within 60 days of AKI event; main AKI definition;  
60-day follow-up definitiona
n=1,542 n=1,965 n=516
Baseline period Reference Reference Reference
Days after infection:
1–7 9.05 (7.31, 11.21) 5.25 (4.15, 6.64) 50.14 (38.36, 65.52)
8–14 4.12 (3.09, 5.48) 2.50 (1.83, 3.41) 8.21 (4.77, 14.12)
15–28 2.50 (1.92, 3.26) 1.38 (1.02, 1.87) 4.50 (2.66, 7.61)
Notes: aFollow-up ends at the earliest of death, the end of registration, last collection date from GP, or 30/60/90 days after the end of first break in the treatment of 30/60/90 
days or more. IRR denotes age-adjusted incidence ratio; age-adjusted in the following age bands: 18–44, 45–54, 55–59, 60–64, 65–69, 70–74, 75–84, 85–89, and 90+ years. 
bAdjusted for calendar time using the following periods: 1997–2000, 2001–2004, 2005–2008, 2009–2011, and 2012–2014.
Abbreviations: AKI, acute kidney injury; GP, general practitioner; ICD-10, International Classification of Diseases Version 10; IRR, incidence rate ratio.
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